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Abstract
Background: The benefits of chronic coronary total occlusion (CTO) percutaneous coronary interven-
tion (PCI) are being questioned. The aim of this studywas to assess the effects of CTO PCI on absolute
myocardial perfusion, as comparedwith PCI of hemodynamically significant non-CTO lesions.
Methods: Consecutive patients with a preserved left ventricular ejection fraction (≥50%) and a
CTO or non-CTO lesion, in whom [15O]H2O positron emission tomography was performed prior
and after successful PCI, were included. Change in quantitative (hyperemic) myocardial blood
flow (MBF), coronary flow reserve (CFR) and perfusion defect size (in myocardial segments)
were compared between CTOs and non-CTO lesions.
Results: In total 92 patients with a CTO and 31 patients with a non-CTO lesion were included.
CTOs induced larger perfusion defect sizes (4.51  1.69 vs. 3.23  2.38 segments, P < 0.01)
with lower hyperemic MBF (1.30  0.37 vs. 1.58  0.62 mLmin−1g−1, P < 0.01) and similarly
impaired CFR (1.66  0.75 vs. 1.89  0.77, P = 0.17) compared with non-CTO lesions. After PCI
both hyperemic MBF and CFR increased similarly between groups (P = 0.57 and 0.35) to normal
ranges with higher hyperemic MBF values in non-CTO compared with CTO (2.89  0.94
vs. 2.48  0.73 mLmin−1g−1, P = 0.03). Perfusion defect sizes decreased similarly after CTO
PCI and non-CTO PCI (P = 0.14), leading to small residual defect sizes in both groups (1.15 
1.44 vs. 0.61  1.45 segments, P = 0.054).
Conclusions: Myocardial perfusion findings are slightly more hampered in patients with a CTO before
and after PCI. Percutaneous revascularization of CTOs, however, improves absolute myocardial perfu-
sion similarly to PCI of hemodynamically significant non-CTO lesions, leading to satisfying results.
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1 | INTRODUCTION
Chronic coronary total occlusions (CTOs) are diagnosed in approxi-
mately one fifth of patients with coronary artery disease (CAD).1 Due
to historically low success rates, increased complication rates, and
concerns regarding patient benefit, only the minority of patients with
a CTO is referred for percutaneous coronary intervention (PCI).1–3
Recently, the development of the “hybrid approach”, an algorithm for
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treating CTOs in a most safe, effective, and efficient way, has resulted
in high success and acceptable complication rates.4,5 Ischemic burden
comprising >10% of the left ventricle due to CAD holds prognostic
relevance, and several studies have shown extensive ischemia to be
present in nearly all patients with a CTO.6–11 Therefore, next to symp-
tom recognition and viability detection, ischemia detection forms one
of the pillars in judicious patient selection for CTO PCI. Major reduc-
tions in ischemia can be achieved after CTO PCI, however, it is more
conservatively employed compared with PCI of a non-CTO
lesion.12–14 [15O]H2O positron emission tomography (PET) is the gold
standard for non-invasive myocardial perfusion imaging, reflecting the
composite of the epicardial as well as the microvascular bed, and
enabling absolute quantification of myocardial perfusion.15 The aim of
this study was to compare the effects of PCI among CTO versus non-
CTO lesions on quantitative myocardial blood flow (MBF) and perfu-
sion defect size.
2 | MATERIALS AND METHODS
2.1 | Study design and participants
The study population consisted of consecutive prospectively recruited
patients successfully treated with a clinically indicated PCI of a CTO
(CTO group) or hemodynamically significant non-CTO lesion (non-
CTO group) between 2012 and 2017 at the VU University Medical
Center. Inclusion criteria were [15O]H2O PET imaging prior and after
PCI, and a preserved left ventricular ejection fraction (LVEF, ≥50%) to
guarantee viable myocardium at the vascular territory of the coronary
lesion. Exclusion criteria were the occurrence of myocardial infarction
(MI) or myocardial revascularization between the index (staged) PCI
procedure and PET imaging post-PCI, contraindications to adenosine
and pregnancy. Patients with a CTO were selected from a dedicated
program with two experienced CTO operators (PK and AN), in which
ischemia- and viability testing is used for patient selection for CTO
PCI. Patients in the non-CTO group were selected from the previously
published PACIFIC-trial, comprising only patients without a cardiac
history.15 The study was approved by the institutional Medical Ethics
Review Committee and all patients provided written informed
consent.
2.2 | Angiographic characteristics
A CTO was defined as a luminal occlusion on invasive coronary angi-
ography for an estimated time of ≥3 months with no or minimal con-
trast penetration through the lesion (thrombolysis in myocardial
infarction [TIMI] flow grades 0–I).16 The Japanese CTO score (J-CTO)
was calculated and CTO PCI was performed according to the hybrid
approach, using antegrade wire escalation (AWE), antegrade dis-
section and reentry (ADR), retrograde wire escalation (RWE), and ret-
rograde dissection and reentry (RDR) techniques5,17. A >90%
diameter stenosis or fractional flow reserve (FFR) of ≤0.80 defined a
hemodynamically significant non-CTO lesion. In case of multivessel
non-CTO PCI, only the vessel with the worst lesion characteristics
regarding stenosis severity or FFR value was included for analysis.
Procedural success was defined as <30% diameter stenosis and TIMI
flow grade III without any major side branch loss. Cardiac biomarkers
were obtained if periprocedural MI was suspected, which was subse-
quently scored according to the Third Universal Definition of MI.18
2.3 | Positron emission tomography
[15O]H2O PET perfusion scans were performed as described previ-
ously.9 Briefly, a dynamic emission scan was performed at rest fol-
lowed by an identical scan during administration of intravenous
adenosine (140 μkg−1min−1). Coronary flow reserve (CFR) was calcu-
lated as the ratio of hyperemic to rest MBF. Perfusion defect size
associated with a (non-)CTO lesion was defined by the number of
myocardial segments in which hyperemic MBF was below 2.3
mLmin−1g−1 and <75% compared with hyperemic MBF in a normal
reference vascular territory. The standardized 17-segment model of
the American Heart Association was used for left ventricular
segmentation.19
2.4 | Statistical analyses
Continuous variables are presented as mean values  SD, whereas
categorical variables are expressed as actual numbers, unless other-
wise stated. Continuous variables were analyzed using the
independent-samples t test and paired-samples t test in case of nor-
mally distributed data, and the Mann–Whitney U test and Wilcoxon
signed-rank test in case data was not normally distributed. Categorical
variables were analyzed using the Fisher’s Exact Test for binary data
and the Chi-squared test for ordinal data. Comparisons between
groups in MBF and perfusion defect size were analyzed using a linear
regression analysis adjusted for age and gender. A level of P < 0.05
was considered significant. Statistical analyses were performed using
SPSS software (IBM SPSS Statistics 22.0, Chicago, IL).
3 | RESULTS
3.1 | Patient population
Clinical characteristics of the included 92 patients with a CTO and
31 patients with a hemodynamically significant non-CTO lesion are
listed in Table 1. Patients with a CTO had more cardiac risk factors
(2.6  1.2 vs. 1.8  1.1; P = 0.01) as compared with patients with a
non-CTO lesion. As a result of different patient cohorts, only subjects
with a CTO had suffered before from major cardiac events, including
prior MI in the CTO territory in 25% of patients.
3.2 | Angiographic characteristics
A CTO was located in the right coronary artery in 70% of patients
(Table 2). The J-CTO score was 0–1, 2, and ≥3 in 46, 29, and 25% of
CTO lesions, and the successful crossing technique was AWE, ADR,
RWE, and RDR in 44, 23, 9, and 25% of patients, respectively. Non-
CTO lesions were predominantly located in the left anterior descend-
ing artery (LAD, 68%). Three of these lesions had a >90% diameter
stenosis and the remaining target lesions were determined
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hemodynamically significant with a mean FFR of 0.55  0.19. The
number of vessel disease and the number of vessel PCI was equally
distributed between groups. Staged PCI was performed in two
patients with a CTO in which another non-CTO lesion was treated
first, and in none of the patients in the non-CTO group. Periproce-
dural MI occurred in six patients treated by CTO PCI (four times after
an RDR technique and two times after an ADR technique) due to the
loss of a minor right ventricular branch (in five patients) or a temporar-
ily obstructed side branch during subintimal wiring (in one patient).
3.3 | Recovery after CTO PCI
Rest MBF in the myocardial area subtended by the CTO was 0.86 
0.25 and did not change after PCI (p = .95) (Table 3). In contrast,
hyperemic MBF significantly increased after PCI (from 1.30  0.37 to
2.48  0.73 mLmin−1g−1; P < 0.01), as did the CFR (from 1.66 
0.75 to 3.03  1.05; P < 0.01). The perfusion defect size significantly
decreased from 4.51  1.69 to 1.15  1.44 segments (P < 0.01). In
remote areas, hyperemic MBF was 2.69  0.69 and 2.70  0.73
mLmin−1g−1 at baseline and follow-up (P < 0.01 and P = 0.048 as
compared with the CTO area), respectively. Additional analyses dem-
onstrated that all PET perfusion results were comparable (P > 0.05)
between CTO patients with (n = 23) and without (n = 69) documented
prior MI in the myocardium subtended by the CTO. In addition, the
above mentioned MBF indices and residual perfusion defect size after
TABLE 1 Baseline characteristics
CTO
(n = 92)
Non-CTO
(n = 31)
P
value
Age (years) 62  10 57  9 0.02
Male 74 (80) 26 (84) 0.79
Body mass index (kgċm−2) 27.8  4.0 26.5  3.5 0.11
Previous MI 33 (36) 0 (0) NA
Previous MI in TV area 23 (25) 0 (0) NA
Q-wave 8 (9) 0 (0) NA
Q-wave in TV area 6 (7) 0 (0) NA
Previous PCI 64 (70) 0 (0) NA
Post-CABG 10 (11) 0 (0) NA
CAD risk factors
Hypertension 56 (61) 8 (26) <0.01
Hypercholesterolemia 47 (51) 12 (39) 0.30
Current smoking 28 (30) 5 (16) 0.16
History of smoking 40 (44) 18 (58) 0.21
Family history CAD 44 (48) 17 (55) 0.54
Diabetes 25 (27) 2 (7) 0.02
Number of CAD risk
factors
2.6  1.2 1.8  1.1 0.01
Medication
Aspirin 87 (95) 30 (97) 1.00
Dual anti-platelets 60 (65) 0 (0) <0.01
Anticoagulant 5 (5) 0 (0) 0.33
Statins 79 (86) 25 (81) 0.57
Beta-blockers 76 (83) 21 (68) 0.13
Calcium channel
blockers
24 (26) 9 (29) 0.82
Long-acting nitrates 25 (27) 3 (10) 0.05
Clinical presentation
Free of symptoms 15 (16) 1 (3) 0.07
Stable angina 47 (51) 22 (71) 0.06
Dyspnea on exertion 16 (17) 1 (3) 0.07
Atypical symptoms 11 (12) 7 (23) 0.15
Unstable angina 2 (2) 0 (0) 1.00
Non-ST elevation MI 1 (1) 0 (0) 1.00
Values are mean  SD or n (%).Abbreviations: CABG, coronary artery
bypass graft surgery; CAD, coronary artery disease; CTO, chronic coronary
total occlusion; MI, myocardial infarction; NA, not applicable; PCI, percuta-
neous coronary intervention; TV, target vessel.
TABLE 2 Angiographic characteristics
CTO
(n = 92)
Non-CTO
(n = 31)
P
value
Target vessel <0.01
Right coronary artery 64 (70) 3 (10)
Left anterior descending
artery
16 (17) 21 (68)
Left circumflex coronary
artery
12 (13) 7 (23)
Number of vessel disease 0.74
Single vessel 62 (67) 21 (68)
Two vessel 25 (27) 7 (23)
Three vessel 5 (5) 3 (10)
Number of vessel PCI 0.60
Single vessel 73 (79) 22 (71)
Two vessel 16 (17) 7 (23)
Three vessel 3 (3) 2 (7)
Values are n (%). P values indicate the overall difference between groups.
Abbreviations: CTO, chronic coronary total occlusion; PCI, percutaneous
coronary intervention.
TABLE 3 Quantitative MBF in patients treated with CTO PCI vs
non-CTO PCI
CTO
(n = 92)
Non-CTO
(n = 31)
P
value
Rest MBF pre-PCI 0.86  0.25 0.83  0.15 0.52
Rest MBF post-PCI 0.86  0.22 0.97  0.29 0.03
P value 0.95 <0.01
Δ rest MBF 0.00  0.23 0.13  0.23 <0.01
Hyperemic MBF
pre-PCI
1.30  0.37 1.58  0.62 <0.01
Hyperemic MBF
post-PCI
2.48  0.73 2.89  0.94 0.03
P value <0.01 <0.01
Δ hyperemic MBF 1.18  0.68 1.31  1.07 0.57
CFR pre-PCI 1.66  0.75 1.89  0.77 0.17
CFR post-PCI 3.03  1.05 3.10  0.79 0.94
P value <0.01 <0.01
Δ CFR 1.37  1.12 1.21  0.97 0.35
Values are mean  SD. MBF per mLmin−1g−1. Outcomes are calculated
using a linear regression analysis adjusted for age and gender.Abbrevia-
tions: Δ, change in MBF; CFR, coronary flow reserve; CTO, chronic coro-
nary total occlusion; MBF, myocardial blood flow; PCI, percutaneous
coronary intervention.
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CTO PCI did not differ between patients with and without periproce-
dural MI (all comparisons P > 0.05). Successful intraplaque crossing
and stenting (AWE or RWE) resulted in relatively higher hyperemic
MBF values after PCI than with a successful dissection and reentry
(DR) technique (2.67  0.76 vs. 2.28  0.65 mLmin−1g−1; P = 0.02),
whilst MBF during rest (P = 0.56), CFR (P = 0.12) and the residual per-
fusion defect size (P = 0.25) were comparable. At follow-up, residual
ischemia was present in the CTO area in one patient due to a signifi-
cant stenosis distal to the (former) CTO lesion, and two other patients
had residual ischemia in a non-target vessel. After follow-up PET
imaging and clinical evaluation, these patients were treated by
additional PCI.
3.4 | Recovery after non-CTO PCI
Rest MBF (from 0.83  0.15 to 0.97  0.29 mLmin−1g−1; P < .01),
hyperemic MBF (from 1.58  0.62 to 2.89  0.94 mLmin−1g−1;
P < 0.01) and CFR (from 1.89  0.77 to 3.10  0.79; P < 0.01) in the
myocardial area subtended by non-CTO lesions increased after PCI.
The perfusion defect size was reduced from 3.23  2.38 to 0.61 
1.45 segments (P < 0.01). In remote areas, hyperemic MBF was
2.82  0.69 and 3.05  0.92 mLmin−1g−1 at baseline and follow-up
(P < 0.01 and p = .51 as compared with the non-CTO lesion area),
respectively. In none of the patients there was a clinical indication for
re-invasive coronary angiography after follow-up imaging.
3.5 | Effects of CTO PCI versus non-CTO PCI on
quantitative MBF
Patient examples of recovery of MBF after CTO PCI as well as non-
CTO PCI are demonstrated in Figure 1. Baseline rest MBF in the myo-
cardial area subtended by a CTO and by a non-CTO lesion was similar
(P = 0.52) and increased after PCI in the non-CTO group only
(P < 0.01) to higher levels compared with the CTO group at follow-up
(P = 0.03) (displayed in Figure 2 and Table 3). Baseline hyperemic MBF
was lower in patients with a CTO compared with patients with a non-
CTO lesion (P < 0.01). The increase in hyperemic MBF was significant
and equivalent after both CTO PCI and non-CTO PCI (P = 0.57). How-
ever, higher hyperemic MBF values were maintained in the non-CTO
group after PCI (P = 0.03). In the vascular territory of CTOs and non-
CTO lesions, CFR values were comparable at baseline (P = 0.17), and
improved equally in both groups (P = 0.35) yielding comparable CFR
levels after PCI (P = 0.94). As mentioned earlier, the extents of vessel
disease and subsequent vessel PCI were similar between groups and
regional PET perfusion results were not different between patients with
one, two and three vessel disease (all comparisons P > 0.05).
3.6 | Effects of CTO PCI versus non-CTO PCI on
perfusion defect size
The perfusion defect size, as measured in myocardial segments, com-
prised at baseline more myocardium in patients with a CTO compared
with patients with a non-CTO lesion (P < 0.01) (Figure 3). The effect
of PCI on the perfusion defect size was similar in both groups
(P = 0.14), resulting in insignificantly different and small residual perfu-
sion defect sizes (P = 0.054).
4 | DISCUSSION
This study is the first head-to-head comparison between the effects of
percutaneous revascularization of CTOs and hemodynamically signifi-
cant non-CTO lesions on quantitative MBF and perfusion defect size.
The main findings are as follows: (1) CTOs subtend a more extensive
perfusion defect size with lower MBF during hyperemia compared with
non-CTO lesions; (2) CTO PCI and non-CTO PCI yield significant and
comparable improvements in hyperemic MBF, CFR, and perfusion
defect size; (3) after both CTO PCI and non-CTO PCI satisfying results
in quantitative MBF and perfusion defect size are achieved.
4.1 | Patient selection and characteristics
Patients with a CTO had a more severe cardiac risk profile compared
with patients with non-CTO lesions. 25% of patients with a CTO suf-
fered from prior MI even though only patients with preserved LVEF
were included in this analysis. The patient groups were selected from
prior studies with different in- and exclusion criteria, which can (par-
tially) explain these differences. However, patients with a CTO are
known to have more extensive CAD and comorbidity than patients
with CAD without a CTO.1 All PET perfusion results were corrected
for age and gender when comparing between groups, and by selecting
patients with a preserved LVEF only, the extent and influence of pre-
vious MI was attempted to be minimized.
4.2 | The influence of a CTO versus a non-CTO
lesion on myocardial perfusion
To achieve a genuine comparison between CTOs and non-CTO lesions,
only FFR defined hemodynamically significant lesions were included in
the non-CTO group. Thresholds for significant CAD with [15O]H2O
PET (hyperemic MBF: 2.3 mLmin−1g−1, and CFR: 2.5) have been well
established previously after validation with FFR, and in this study, in
both groups baseline hyperemic MBF and CFR were indicative for sig-
nificant CAD.20 At baseline, rest MBF and CFR values were comparable
in patients with a CTO and patients with a non-CTO lesion. On the
contrary, baseline hyperemic MBF was lower and the associated perfu-
sion defect size was more extensive in the CTO group. These findings
may be expected given the absence of antegrade flow and the com-
plete dependence on collateral supply in CTOs. Previous studies have
consistently demonstrated that well-developed collaterals cannot pre-
serve adequate blood supply to a CTO territory during increased
demand.9–11 In addition, prior MI, although sometimes unrecognized in
patients with a CTO, and microvascular dysfunction, are regularly pre-
sent in the myocardial area supplied by a CTO.21,22 Additional analyses
in this study showed comparable PET perfusion results between CTO
patients with and without documented prior MI in the myocardium
subtended by the CTO. However, the combined effect of a higher prev-
alence of CAD risk factors, prior (unrecognized) MI, and prior revascu-
larization in patients with a CTO could hypothetically have led to
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relatively more microvascular disease in the CTO area, (partially) caus-
ing diminished hyperemic MBF and (non-significantly) lower CFR in
these patients.23 Using [15O]H2O PET perfusion, it has previously been
shown that MBF during hyperemia is inversely related to the extent of
surrounding scar tissue in patients with a CTO.13
4.3 | Effects of CTO PCI versus non-CTO PCI on
myocardial perfusion
A significant increase in rest MBF was seen after non-CTO PCI, whilst
no change occurred after CTO PCI. Hypothetically this increase after
non-CTO PCI can be the recovery of chronic hypoperfusion in former
hibernating myocardium. Overall viability in the target vessel territory
was preserved in all individuals. However, 25% of patients in the CTO
group had suffered previously from MI in the vascular territory of the
CTO, and this might have resulted in relatively less hibernating myo-
cardium present in these patients at baseline. Improvement in hyper-
emic MBF and CFR after CTO PCI and non-CTO PCI was comparable,
leading to normalization of the above-mentioned indices in both
patient groups.20 Still, relatively higher MBF levels during hyperemia
were observed after PCI in the non-CTO group. With lower levels at
baseline and in the presence of potentially more microvascular
FIGURE 1 MBF restoration after percutaneous revascularization of a CTO and a non-CTO lesion. (1A) MBF during hyperemia was severely
reduced in the myocardial area distal of a CTO in the RCA (arrow: proximal cap, arrowhead: Distal cap) despite collateral supply by septal
collaterals and a very well-developed epicardial collateral arising from the LCx. (1B) successful percutaneous revascularization of the CTO (arrow)
resulted in restoration of hyperemic MBF. (2A) a severe non-CTO lesion in the LAD with an FFR of 0.18 (arrow) induced severely decreased
hyperemic MBF, which recovered after successful PCI (2B, arrow). Abbreviations: CTO, chronic coronary total occlusion; FFR, fractional flow
reserve; LCx, left circumflex coronary artery; MBF, myocardial blood flow; PCI, percutaneous coronary intervention; RCA, right coronary artery
[Color figure can be viewed at wileyonlinelibrary.com]
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dysfunction (vide supra), the demonstrated hyperemic MBF levels
achieved after CTO PCI, which were slightly lower as compared with
remote areas, probably represent the optimal results for these
patients. Because the majority of the CTO lesions were located in the
RCA (70%) and most non-CTO lesions in the LAD (68%), the higher
hyperemic MBF levels in patients with non-CTO lesions could theo-
retically be caused by the disparity of target vessels between groups.
In an additional analysis in the total cohort of patients comparing tar-
get lesions in the RCA with target lesions in the LAD, however,
comparable hyperemic MBF levels were found at baseline (P = 0.52),
at follow-up (P = 0.70), and in change of hyperemic MBF (P = 0.98).
Another possible explanation for relatively lower (although already
normalized) hyperemic MBF levels after CTO PCI would be the proce-
dure leading to suboptimal results. Because the vessel is totally
occluded, a CTO can be crossed through the luminal plaque or around
the lesion through the subintimal space by means of a DR technique.
Higher rates of restenosis and repeat target vessel revascularization
after the usage of wire-based DR techniques have been reported pre-
viously.24,25 After the introduction of more controlled device-based
DR techniques, however, wire-based DR techniques are increasingly
being used as a bailout strategy when other strategies in CTO PCI fail.
This development has led to acceptable repeat revascularization rates
after usage of DR techniques comparable with intraplaque crossing
techniques.26 In this study in the CTO group, intraplaque crossing and
stenting resulted in relatively higher hyperemic MBF after PCI com-
pared with a successful DR technique. The (inappropriate) usage of a
DR technique can lead to long dissection planes with a potential for
side branch loss, longer stent lengths and stent under-sizing due to
hematoma formation, and in this study these unfavorable features
could hypothetically have led to less recovery of hyperemic MBF.
However, the recently published results of the randomized
IMPACTOR-CTO trial showed that only a marginal nonsignificant
reduction in ischemic burden could be realized with optimal medical
therapy alone (without successful crossing and stenting) in patients
with a CTO.27 Although hyperemic MBF after the usage of DR tech-
niques was relatively lower in this study, it should be noted that these
techniques led to successful CTO crossing and subsequent reduction
in ischemic burden in 48% of the patients, and they can be considered
as essential additives in CTO PCI.5 The potential differences in resto-
ration of myocardial perfusion after intraplaque crossing and DR
FIGURE 2 Per patient quantitative MBF during rest (A) and
hyperemia (B) and CFR (C) are displayed for patients with a CTO and
patients with a non-CTO lesion before PCI, after PCI and the change
in between. Error bars display mean  SEM. Corresponding values are
mean  SD. CFR, coronary flow reserve. Other abbreviations as in
Figure 1 [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 3 Perfusion defect size in myocardial segments before and
after PCI of a CTO and a non-CTO lesion. At baseline, the average
perfusion defect size was significantly more comprehensive in the
CTO group compared with the non-CTO group. Percutaneous
revascularization led to significant improvements with small residual
perfusion defects in both groups as a result. Error bars display mean 
SEM. Corresponding values are mean  SD. Abbreviations: CTO,
chronic coronary total occlusion; FFR, fractional flow reserve; LCx,
left circumflex coronary artery; MBF, myocardial blood flow; PCI,
percutaneous coronary intervention; RCA, right coronary artery [Color
figure can be viewed at wileyonlinelibrary.com]
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techniques in CTO PCI should be further investigated in more detail in
a larger patient cohort. Reductions in perfusion defect size were on
average 3.36 and 2.61 segments after CTO PCI and non-CTO PCI,
representing 21 and 16% of the left ventricle myocardium respectively,
and can be considered as clinically relevant.28 After PCI, residual perfu-
sion defect sizes in both groups of patients were rather small (<10% of
the left ventricle), and in case of refractory complaints, further optimiza-
tion of medical therapy would be appropriate in these patients.8
4.4 | CTO PCI and non-CTO PCI: Different
procedures with comparable effects
In stable patients with equivalent myocardial ischemia and symptom
severity, CTO PCI is applied more conservatively than PCI of a (hemo-
dynamically significant) non-CTO lesion.14 This study shows that both
treatments lead to similar and satisfying improvements in terms of
quantitative MBF and perfusion defect size if patients are appropri-
ately selected based on ischemia prior to revascularization. Approxi-
mately half of the CTOs had morphologic characteristics of high
anatomic complexity (J-CTO score of ≥2). With all incorporated tech-
niques to revascularize CTO lesions, high anatomic complexity of a
CTO becomes less of a boundary to achieve satisfying results, which
is illustrated by the recovery of perfusion after CTO PCI in this study.
This study adds to the scarce body of evidence that among patients
with ischemia as indication for revascularization, CTO PCI should be
applied in a similar way as non-CTO PCI. With contemporary high suc-
cess and acceptable complication rates in CTO PCI, it is a treatment
strategy that should readily be considered albeit with appropriate
patient selection.5,29
4.5 | Limitations
Only patients with a LVEF ≥50% were selected and present results
cannot be extrapolated to patients with lower LVEF values. Patients
in the non-CTO group were referred to the cathlab irrespectively of
PET perfusion results according to the study protocol. In patients with
a CTO, non-invasive ischemia detection was used for appropriate
patient selection for revascularization. This could have led to the
selection of CTOs with relatively more ischemic burden. Regional PET
perfusion results were comparable between LAD and RCA lesions and
in patients with one, two, or three vessel disease. It cannot be
excluded, however, that more detailed inequalities in lesion location
and extent of disease have diluted the comparison between the
effects of CTO PCI and non-CTO PCI. Cardiac biomarkers were not
obtained systematically and the influence of potentially unrecognized
periprocedural myocardial injuries in the CTO group (especially after
retrograde approaches) on the follow-up PET perfusion results is
unclear.30 With lack of angiographic control at time of follow-up PET
imaging, it cannot be excluded that recurrent luminal narrowing has
influenced the results in a negative manner in some patients. The
mean time interval between PCI and follow-up PET was 110 days in
the CTO group and 23 days in the non-CTO group due to different
imaging protocols in the two patient cohorts. With absence of reste-
nosis, a gradual increase of perfusion after angioplasty at 1 week and
3 months follow-up has been reported previously.31 If the duration
between PCI and follow-up PET imaging in the non-CTO group would
have been longer, this could potentially have led to more advanta-
geous results. The recently published results of the randomized sham-
controlled ORBITA trial showed comparable improvements in patient
health status after PCI and optimal medical therapy despite the signifi-
cant improvements in invasive and non-invasive perfusion indices
after PCI.32 In this study, patient symptoms were not systematically
obtained after PCI during follow-up, and therefore lacks the explora-
tion of a possible correlation between improvement of (hyperemic)
MBF and patient symptoms or quality of life.
5 | CONCLUSION
In general, hyperemic myocardial perfusion is slightly more hampered
in patients with a CTO before and after PCI. Percutaneous revasculari-
zation of CTOs, however, improves hyperemic MBF, CFR, and the
perfusion defect size similar to PCI of hemodynamically significant
non-CTO lesions, leading to satisfying results.
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